Follow us on:

Linkedin Facebook

Cambridge Cognition to announce preliminary results on 12 April 2022

Cambridge Cognition
[shareaholic app="share_buttons" id_name="post_below_content"]

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will announce its preliminary results for the year ended 31 December 2021 on 12 April 2022.

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

Latest Company News

Cambridge Cognition

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc announces the formation of a Scientific Advisory Board to guide brain health strategies and market trends effectively.
Cambridge Cognition

Cambridge Cognition and ActiGraph announce strategic partnership for Advanced CNS Clinical Trials

Cambridge Cognition Holdings plc partners with ActiGraph to enhance brain health assessments in clinical trials, aiming to improve treatments for CNS disorders.
Cambridge Cognition

Cambridge Cognition appoints Stuart Gall and Philip Rodgers as Non-Executive Directors to support growth plans

Cambridge Cognition Holdings plc has announced the appointment of Stuart Gall and Philip Rodgers as independent non-executive Directors, to support the company's growth plans in the healthcare and technology sectors.
Cambridge Cognition

Cambridge Cognition Holdings Grant of Options for Long Term Incentive Plan

Cambridge Cognition

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LLP

Cambridge Cognition

Cambridge Cognition launches its automated quality assurance for clinical trials

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.